Therapeutic cancer vaccines: Navigating clinical translation and multimodal synergy - Takeaways - MDSpire

Therapeutic cancer vaccines: Navigating clinical translation and multimodal synergy

  • By

  • Chu, Tan-Huy

  • Huynh, Thuy Linh

  • Phuong, Le-Tri

  • April 13, 2026

  • 0 min

Share

  • 1

    Therapeutic cancer vaccines (TCVs) can induce strong T cell responses against cancer but face challenges in achieving reliable clinical outcomes.

  • 2

    Key challenges for TCVs include manufacturing issues, the immunosuppressive tumor microenvironment, and patient variability.

  • 3

    The review discusses the transition from monotherapy to combination strategies for TCVs to improve efficacy.

  • 4

    A translational framework is proposed for strategically using TCVs to target minimal residual disease (MRD).

  • 5

    Addressing the challenges of TCVs through rational strategies and better patient selection could enhance future clinical applications.

Original Source(s)

Therapeutic cancer vaccines: Navigating clinical translation and multimodal synergy

  • by Chu, Tan-Huy , Huynh, Thuy Linh , Phuong, Le-Tri

  • April 13, 2026

Related Content

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma